Dabora SL - Search Results

1

Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors.

Woodrum C, Nobil A, Dabora SL. Woodrum C, et al. Among authors: dabora sl. J Transl Med. 2010 Feb 10;8:14. doi: 10.1186/1479-5876-8-14. J Transl Med. 2010. PMID: 20146790 Free PMC article.

2

Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models.

Lee N, Woodrum CL, Nobil AM, Rauktys AE, Messina MP, Dabora SL. Lee N, et al. Among authors: dabora sl. BMC Pharmacol. 2009 Apr 15;9:8. doi: 10.1186/1471-2210-9-8. BMC Pharmacol. 2009. PMID: 19368729 Free PMC article.

3

Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease.

Dabora SL, Franz DN, Ashwal S, Sagalowsky A, DiMario FJ Jr, Miles D, Cutler D, Krueger D, Uppot RN, Rabenou R, Camposano S, Paolini J, Fennessy F, Lee N, Woodrum C, Manola J, Garber J, Thiele EA. Dabora SL, et al. PLoS One. 2011;6(9):e23379. doi: 10.1371/journal.pone.0023379. Epub 2011 Sep 6. PLoS One. 2011. PMID: 21915260 Free PMC article. Clinical Trial.

4

Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model.

Rauktys A, Lee N, Lee L, Dabora SL. Rauktys A, et al. Among authors: dabora sl. BMC Dermatol. 2008 Jan 28;8:1. doi: 10.1186/1471-5945-8-1. BMC Dermatol. 2008. PMID: 18226258 Free PMC article.

5

Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779.

Messina MP, Rauktys A, Lee L, Dabora SL. Messina MP, et al. Among authors: dabora sl. BMC Pharmacol. 2007 Nov 6;7:14. doi: 10.1186/1471-2210-7-14. BMC Pharmacol. 2007. PMID: 17986349 Free PMC article.

6

Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models.

Lee L, Sudentas P, Donohue B, Asrican K, Worku A, Walker V, Sun Y, Schmidt K, Albert MS, El-Hashemite N, Lader AS, Onda H, Zhang H, Kwiatkowski DJ, Dabora SL. Lee L, et al. Among authors: dabora sl. Genes Chromosomes Cancer. 2005 Mar;42(3):213-27. doi: 10.1002/gcc.20118. Genes Chromosomes Cancer. 2005. PMID: 15578690

7

Combination of a rapamycin analog (CCI-779) and interferon-gamma is more effective than single agents in treating a mouse model of tuberous sclerosis complex.

Lee L, Sudentas P, Dabora SL. Lee L, et al. Among authors: dabora sl. Genes Chromosomes Cancer. 2006 Oct;45(10):933-44. doi: 10.1002/gcc.20357. Genes Chromosomes Cancer. 2006. PMID: 16845661

8

Malinowska IA, Lee N, Kumar V, Thiele EA, Franz DN, Ashwal S, Sagalowsky A, Dimario FJ Jr, Cutler D, Krueger D, Camposano S, Paolini J, Dabora SL. Malinowska IA, et al. Among authors: dabora sl. PLoS One. 2013;8(2):e56199. doi: 10.1371/journal.pone.0056199. Epub 2013 Feb 20. PLoS One. 2013. PMID: 23437092 Free PMC article. Clinical Trial.

9

Identification of 54 large deletions/duplications in TSC1 and TSC2 using MLPA, and genotype-phenotype correlations.

Kozlowski P, Roberts P, Dabora S, Franz D, Bissler J, Northrup H, Au KS, Lazarus R, Domanska-Pakiela D, Kotulska K, Jozwiak S, Kwiatkowski DJ. Kozlowski P, et al. Hum Genet. 2007 May;121(3-4):389-400. doi: 10.1007/s00439-006-0308-9. Epub 2007 Feb 8. Hum Genet. 2007. PMID: 17287951

10

A 34 bp deletion within TSC2 is a rare polymorphism, not a pathogenic mutation.

Roberts PS, Ramesh V, Dabora S, Kwiatkowski DJ. Roberts PS, et al. Ann Hum Genet. 2003 Nov;67(Pt 6):495-503. doi: 10.1046/j.1529-8817.2003.00059.x. Ann Hum Genet. 2003. PMID: 14641237

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

26 results

Search Page